HER2 Support Group Forums - Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast

HER2 Support Group Forums (https://her2support.org/vbulletin/index.php)

- General Cancer News (https://her2support.org/vbulletin/forumdisplay.php?f=45)

- - Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast (https://her2support.org/vbulletin/showthread.php?t=61538)

News	07-25-2014 02:21 AM

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

More...

All times are GMT -7. The time now is 04:07 AM.